Sharemaestro Newsreel

HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating Hims & Hers Health, Inc. (NYSE:HIMS) following a lawsuit filed by the FTC and California alleging violations of federal securities laws and unlawful business practices. The lawsuit claims Hims & Hers failed to disclose prescription charges, made …

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also …

Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal …

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues …

Rigetti Q2 Earnings Miss Estimates on Higher Costs, Revenue Beat

Rigetti Computing RGTI reported second-quarter 2026 adjusted loss per share of 5 cents, wider than 4 cents in the prior-year quarter. The metric also missed the Zacks Consensus Estimate of earnings by 66.7%. GAAP loss per share in the reported quarter was 16 cents …

Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2026 results on Aug. 10, after the closing bell. In the last reported quarter, the company's loss per share of 18 cents lagged the Zacks Consensus Estimate of earnings per share of 4 …

Piper Sandler Reiterates Neutral Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Zoetis (ZTS) Following Earnings And Guidance Cut With A Valuation Question

State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock

State Street Corporation has disclosed a 5.4% stake in Ironwood Pharmaceuticals common stock through a passive Schedule 13G filing. The investment manager beneficially owns 8,809,601 shares, primarily with shared voting and dispositive power through its subsidiaries. This significant ownership makes State Street a key …

Dimensional Fund Advisors LP Grows Stock Holdings in Harrow, Inc. $HROW

Dimensional Fund Advisors LP significantly increased its stake in Harrow, Inc. (NASDAQ:HROW) by 56.4% in the first quarter, now holding 579,520 shares valued at approximately $20.4 million. This comes as Harrow reported weaker-than-expected quarterly results but maintains a "Moderate Buy" consensus rating from analysts …

Amylyx Pharmaceuticals Releases Q2 2026 Financial Results

Amylyx Pharmaceuticals (AMLX) reported a Q2 2026 net loss of $0.39 per share, wider than the $0.37 expected loss, totaling $43.4 million. Despite missing analyst expectations, the company showed a 15.2% improvement from the Q2 2025 loss of $0.46 per share. Wall Street maintains …

Elanco Ends Lobbying Relationship With Stumptown Strategies

Elanco Animal Health Inc. has terminated its lobbying contract with Stumptown Strategies LLC, a firm it paid approximately $10,000 per quarter. The company, which had Blair Larkins as its primary lobbyist, has been advocating for the Innovative FEED Act, legislation aimed at reclassifying certain …

Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS

Dimensional Fund Advisors LP increased its stake in Emergent Biosolutions Inc. by 22.4% to 2.76 million shares, now valued at approximately $22.9 million, making up 5.34% of the company. Despite beating Q2 earnings and revenue estimates, Emergent's stock has fallen 29.6% due to negative …

Trulieve Jumps Over 5% as NYSE Listing and Profit Beat Eclipse Revenue Dip

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential additional payments of up to $12.00 per share via Contingent …

Stocks in play: Canopy Growth Corporation

Canopy Growth Corporation (WEED.TO, CGC) announced its financial results for the first quarter of fiscal year 2027. The company reported a 13% increase in consolidated net revenue to $81.2 million compared to the same period in the previous year, and a 68% lower net …

Viatris’ high-range grind stands out in a generic-drug group short on Trend Signals

VTRS finished the week at $17.56, just 2.8% below its 52-week high, with an active 49-week trend backdrop but only baseline volume confirmation.

Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside

Collegium Pharmaceutical, Inc. (COLL) has seen its average 12-month price target reduced from $53.6 to $51.2 by 5 analysts, with individual forecasts ranging from $43 to $60. Despite this cut, the updated target still implies a significant 43% potential upside from its August 5 …

Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return

Collegium Pharmaceutical (COLL) stock has seen a nearly 60% return over the past five years but may still be trading at a discount. Despite recent weakness, the company screens as undervalued in most measures, with its current P/E ratio of 12.6x being below the …

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06

This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The …

Prestige Consumer Healthcare Stock (PBH) Opinions on Recent Earnings and M&A Activity

Earnings Preview: Kamada to Report Financial Results on August 12

Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside

Emergent BioSolutions Inc. (EBS), a healthcare company specializing in drug manufacturing for public health threats, shows a significant 125.99% potential upside according to analysts, despite a current stock price at the lower end of its 52-week range. The company boasts impressive revenue growth of …

Canopy Growth Narrows Adjusted EBITDA Loss 59% to $3.2M

Canopy Growth Corporation reported its Q1 FY2027 financial results, showing a 13% increase in consolidated net revenue to $81.2 million, with growth across all business segments. The company significantly narrowed its Adjusted EBITDA loss by 59% year-over-year to $3.2 million, attributed to revenue growth …

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Alpha Teknova Inc (TKNO) Stock News Today

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

Alpha Teknova Inc (TKNO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Is Perrigo (PRGO) Still Below Fair Value On Its Earnings Beat?

ANI Pharmaceuticals stock falls 7% despite second quarter beat

ANI Pharmaceuticals Inc. reported better-than-expected second-quarter results but saw its stock fall 7.60% in pre-market trading. This decline was primarily due to the company lowering its full-year guidance for its key Cortrophin Gel product, despite reaffirming overall full-year revenue and adjusted EBITDA/EPS guidance. The …

TSX Value Stock Estimates Featuring Cronos Group And 2 More

This article identifies undervalued TSX stocks based on discounted cash flow, highlighting Cronos Group, Timbercreek Financial, and Lumine Group. It provides an overview of each company's operations, estimated discount to fair value, and recent financial performance, suggesting potential opportunities for investors in the Canadian …

Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates

Canopy Growth Corporation (CGC) reported a Q1 loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a $0.04 loss, and revenue of $58.63 million, slightly exceeding estimates. Despite this, the company's shares have fallen 18.2% year-to-date, contrasting with the S&P 500's gain. …

ZYBT Stock Whipsaws As Speculative Trading Dominates Tape

Zhengye Biotechnology Holding Limited (ZYBT) stock is experiencing extreme volatility due to speculative trading, with large price swings that disconnect from its underlying fundamentals. Despite manageable debt and significant assets, the company shows negative returns on invested capital, indicating it's destroying value. Traders are …

Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $26.7, Implies 22% Upside

Amylyx Pharmaceuticals, Inc. (AMLX) has seen its average 12-month price target raised from $25.56 to $26.7 by 10 analysts, suggesting a 22% potential upside from its August 5th closing price. The consensus rating remains a "Buy" from 11 analysts, with 10 recommending "Buy" and …

Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary

Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased …